Recent trends in brand-name and generic drug competition

@article{Grabowski2014RecentTI,
  title={Recent trends in brand-name and generic drug competition},
  author={H. Grabowski and Genia Long and R. Mortimer},
  journal={Journal of Medical Economics},
  year={2014},
  volume={17},
  pages={207 - 214}
}
  • H. Grabowski, Genia Long, R. Mortimer
  • Published 2014
  • Medicine, Business
  • Journal of Medical Economics
  • OBJECTIVE To provide evidence on recent trends in: (1) market exclusivity periods (MEPs, the time between launch of a brand-name drug and its first generic competitor) for new molecular entities (NMEs); (2) the likelihood and timing of patent challenges under Paragraph IV of the Hatch-Waxman Act; and (3) generic drug penetration. [...] Key MethodMETHODS IMS Health National Sales Perspectives data were used to calculate MEPs for the 257 NMEs experiencing initial generic entry between January 1995 and…Expand Abstract
    52 Citations
    Updated trends in US brand-name and generic drug competition
    • 24
    • PDF
    Strategies That Delay Market Entry of Generic Drugs
    • 20
    • PDF
    Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario
    • 1
    • PDF
    Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.
    An Analysis of Follow‐On Development in New Drug Classes, January 1986–June 2018

    References

    SHOWING 1-10 OF 16 REFERENCES
    Pharmaceuticals in U.S. health care: determinants of quantity and price.
    • E. Berndt
    • Economics, Medicine
    • The journal of economic perspectives : a journal of the American Economic Association
    • 2002
    • 164
    IMS Institute for Healthcare Informatics
    • 122
    Abbreviated New Drug Application and Generics. 2013:1-42. Available at: http://www.fda.gov/downloads/ Drugs
    • Abbreviated New Drug Application and Generics. 2013:1-42. Available at: http://www.fda.gov/downloads/ Drugs
    • 2013
    Analyzing Litigation Success Rates
    • Pharmaceuticals
    • 2010